Informed Prostate Cancer Patient Support

Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New Zealand - Lawless - Journal of Medical Imaging and Radiation Oncology - Wiley Online Library

Functional outcome after radical prostatectomy in 1313 patients: A single‐center study - Haeuser - The Prostate - Wiley Online Library

Metastatic castration resistant prostate cancer | RRU dovepress.com Metastatic castration resistant prostate cancer | RRU Dove Press 61–78 minutes Introduction Prostate cancer (PCa) is the first malignant tumor in male population by incidence and second by death, with 27% of new diagnoses of all incident cancer cases in men every year and 11% of all cancer-related deaths. 1 Localized PCa has survival rates >90% at 5 years, which decrease to 31% in advanced and metastatic settings. 2 Androgen deprivation therapy (ADT) is a backbone therapy for metastatic hormone-sensitive prostate cancer (mHSPC). In years, many other compounds were introduced in the treatment of mHSPC in combination with ADT: chemotherapy (docetaxel), androgen receptor axis targeted therapies (ARATs) such as abiraterone acetate, enzalutamide, apalutamide, and darolutamide. 3 However, most of the patients develop m

The next big advance in cancer treatment could be a vaccine scrippsnews.com The next big advance in cancer treatment could be a vaccine AP 6–8 minutes The next big advance in cancer treatment could be a vaccine. After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years. These aren't traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer. "We're getting something to work. Now we need to get it to work better," said Dr. James Gulley, who helps lead a center at the National Cancer Institute that develops immune therapies, including cancer treatment vaccines. More than ever, scien

Cancer drug shortages should be causing more outrage - STAT

AI cuts treatment time for cancer radiotherapy - BBC News

Clinical outcomes in patients with metastatic castrate‐resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case–control study - Arafa - The Prostate - Wiley Online Library ORIGINAL ARTICLE Ali T. Arafa MD ,  Leah R. Blader PharmD ,  Karan Ramakrishna MD ,  Jeff Engle PharmD, MS ,  Charles J. Ryan MD ,  Nicholas A. Zorko MD, PhD ,  Gautam Jha MD ,  Emmanuel S. Antonarakis MD First published: 19 June 2023 https://doi.org/10.1002/pros.24589 Abstract Introduction Abiraterone and concurrent androgen deprivation therapy (ADT) are used in the treatment of patients with metastatic castration-resistant prostate cancer. Recently, it has been suggested that the use of abiraterone alone (without ADT) may have comparable efficacy to abiraterone with on